A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Eligibility Criteria

• 1. Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF).
• 2. Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM).
• 3. Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Investigator or who are not amenable (intolerability, patient choice) to standard therapies.
• 1. Treatment with any of the following:
• * Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days).
• * Systemic chemotherapy within 14 days.
• * Radiation therapy within 14 days
• * Biologics (Antibodies) treatment within 28 days,
• * Radioimmunoconjugates or toxin conjugates within 12 weeks.
• * Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.
• * Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD.
• 2. History of central nervous system lymphoma/leukemia in remission for less than 2 years.
• 3. Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.